



CLINICAL TRIALS OF TEXAS, INC.

Promoting Health Through Research

Curriculum Vitae

Thomas Wayne Mieras, MD

7940 Floyd Curl Drive, Suite 700
San Antonio, Texas 78229

8401 Datapoint Drive, Suite 401
San Antonio, Texas 78229

EDUCATION

- 1987-1990 Internship and Residency: Internal Medicine, University of Texas Health Science Center at San Antonio, Affiliated Hospitals, San Antonio, Texas
- 1983-1987 Doctor of Medicine, University of Texas Health Science Center at San Antonio School of Medicine, San Antonio, Texas
- 1980-1983 No degree (accepted to medical school after three years of undergraduate education), Texas A&M University College of Science, College Station, Texas
- 1970-1973 Killeen High School, Killeen, Texas

LICENSE(S)

- 1988-Present Texas Medical Board, H4555
- Current DEA Registration
- Current Texas DPS Registration

CERTIFICATION(S)

- 1991 American Board of Internal Medicine, Certificate #137610

PROFESSIONAL EXPERIENCE

- 1999 Community Based Teaching Award, American College of Physicians
- 1998-Present San Antonio Preventive & Diagnostic Medicine, PA, Group practice, Internal Medicine, San Antonio, Texas
- 1996 American College of Physicians, Preceptorship Award, Community Based Teaching Project
- 1992 -1995 Physical Diagnosis, 1st year Medical Students, University of Texas Health Science Center at San Antonio, San Antonio, Texas
- 1992 Internal Medicine Physician, San Antonio Force, Arena Football Team
- 1991-1999 Instructor, Physical Diagnosis, 2nd year Medical Students, University of Texas Health Science Center at San Antonio, San Antonio, Texas
- 1991-1997 Private/Group Practice, Diagnostic Clinic of San Antonio, Internal Medicine
- 1990-1991 Chief Medical Resident: Department of Internal Medicine, University of Texas Health Science Center at San Antonio, San Antonio, Texas
- 1990 Instructor, Dental Residency Physical Diagnosis, University of Texas Health Science Center at San Antonio, San Antonio, Texas
- 1983-1987 Coordinator, Intramural Volleyball, University of Texas Health Science Center at San Antonio, San Antonio, Texas
- 1972-1980 Manager, McDonald's, Killen, Texas
- 1972-1980 McDonald's Restaurant, Killen, Texas

PROFESSIONAL MEMBERSHIPS

- 1991-1994 Society of General Internal Medicine

1991-1993 Bexar County Medical Society
1990-present Member, American College of Physicians
1989-1991 American Medical Association

HOSPITAL AFFILIATION(S)

St. Luke's Baptist Hospital, San Antonio, Texas
Southwest Texas Methodist, San Antonio, Texas

ACADEMIC APPOINTMENTS

1991-Present Clinical Associate Professor of Medicine: Department of Internal Medicine, University of Texas Health Science Center at San Antonio, San Antonio, Texas
1990 - 1991 Instructor of Medicine, Department of Internal Medicine, University of Texas Health Science Center at San Antonio, San Antonio, Texas

PRESENTATIONS

1992 "Clinical Pharmacy: A Physician's Perspective," Central Texas Society of Hospital Pharmacists
1991 "The Role of ACE Inhibitors in the Treatment of Hypertension," Merck-Sharp and Dohme
1991 "The Clinical Significance of β -lactamases," Presented to the Brewster/Pecos County Medical Society
1990 Resident Teaching Conference, "Ehrlichiosis -- a new tick borne disease." A review of the epidemiology, symptoms, diagnosis and treatment."
1989-1990 Medical Jeopardy, a monthly housestaff quiz designed for board review.
1989 Resident Teaching Conference, "Blood Cultures and Bacteremia," an extensive review of the clinical and microbiological implications of bacteremia.

RESEARCH AFFILIATION

2003-Present Investigator, Clinical Trials of Texas, Inc., San Antonio, Texas

RESEARCH EXPERIENCE

2010-Present: Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Efficacy And Safety Study To Evaluate The Effects Of Oral Administration Of "Study Drug" In Patients With Congestive Heart Failure

2009-Present: A Multi-Center, Randomized, Active Controlled Study To Investigate The Efficacy And Safety Of Intravenous "Study Drug" In Patients With Iron Deficiency Anemia (IDA)

2009-Present: A Phase 2a Randomized, Double-Blind, Active Controlled Trial To Evaluate The Safety And Immunogenicity Of A Trivalent "Study Drug" In Older Adults In The United States And India

2009-Present: A 4-Week, Multicenter, Randomized, Double-Blind, Phase 3b Trial To Evaluate The Efficacy Of "Study Drug" In Combination With "Study Drug" Versus Up-Titrated "Study Drug" To 2000 MG In Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control With Diet And Exercise And A Stable Dose Of "Study Drug" 1500 MG

2009-Present: A Randomized, Double-Blind, Placebo- And Active-Controlled, Parallel-Group, Multicenter Study To Determine The Efficacy And Safety Of "Study Drug" When Used In Combination With "Study Drug" Compared With "Study Drug" Plus "Study Drug," "Study Drug" Plus "Study Drug," And "Study Drug" Plus Placebo In Subjects With Type 2 Diabetes Mellitus

2009-Present: A Randomized, Open-Label, Parallel-Group, Multicenter Study To Determine The Efficacy And Long Term Safety Of "Study Drug" Compared With Insulin In Subjects With Type 2 Diabetes Mellitus

2009-Present: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study To Determine The Efficacy And Safety Of "Study Drug" When Used In Combination With "Study Drug" With Or Without "Study Drug" In Subjects With Type 2 Diabetes Mellitus

2009-Present: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study To Determine The Efficacy And Safety Of Two Dose Levels Of "Study Drug" Compared With Placebo In Subjects With Type 2 Diabetes Mellitus

2009-Present: A Randomized, Double-Blind, Placebo- And Active-Controlled, Parallel-Group, Multicenter Study To Determine The Efficacy And Safety Of "Study Drug" Administered In Combination With "Study Drug" And "Study Drug" Compared With "Study Drug" Plus "Study Drug" And Placebo And With "Study Drug" Plus "Study Drug" And "Study Drug" In Subjects With Type 2 Diabetes Mellitus

2009-Present: A Randomized, Double-Blind, Placebo- And Active-Controlled Study Of "Study Drug" In The Treatment Of Neuropathic Pain In Diabetic Peripheral Neuropathy Followed By A Blinded Extension Phase

2008-Present: A Multicenter, Randomized, Controlled Study to Investigate the Safety and Tolerability of a Single Dose of Intravenous "Study Drug" Vs. Standard Medical Care in Treating Iron Deficiency Anemia in Subjects Who Are Not Dialysis Dependent

2008-Present: A Multicenter, Randomized, Controlled Study to Investigate the Safety and Tolerability of Intravenous "Study Drug" vs. Standard Medical Care in Treating Iron Deficiency Anemia

2008-Present: A Phase 3, Multi-Center, Randomized, Double-Blind, Controlled Study Of The Long-Term Analgesic Efficacy And Safety Of "Study Drug" Alone Or In Combination With Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Versus NSAIDs Alone In Patients With Osteoarthritis Of The Knee Or Hip

2008-2009: A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Assess The Efficacy And Safety Of "Study Drug" In The Treatment Of Subjects With Non-Constipation Irritable Bowel Syndrome

2007-2008: Double-Blind Follow-On Safety Study Of "Study Drug" In Subjects Who Have Completed Participation In "Study Protocol" Or "Study Protocol"

2007-2008: A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Dose-Range-Finding, Parallel-Design, Phase 2 Trial Of "Study Drug" Administered To Patients With Irritable Bowel Syndrome With Constipation

2007-2008: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of "Study Drug" In Subjects With Uncomplicated Acute Influenza

2006-2008: A Randomized, Double-Blind, Phase 3 Study Of The Efficacy And Safety Of "Study Drug" In Subjects Requiring NSAID Treatment

2005-2008: A 12-Week, Multicenter, Double-Blind, Randomized Efficacy And Safety Study Of "Study Drug" For The Treatment Of Constipation-Predominant Irritable Bowel Syndrome

2004-2005: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of "Study Drug" For The Treatment Of Painful Diabetic Neuropathy

2004-2005: A 24-Week Randomized, Double-Blind, Double-Dummy, Multicenter Study To Compare The Efficacy Of "Study Drug" And "Study Drug" In Subjects With Type 2 Diabetes Mellitus

2003-2004: A Phase 3, Randomized, Double-Blind, Active-Controlled, Multicenter Trial To Evaluate The Safety And Efficacy Of An Investigational Drug In Combination With Metformin Compared To "Study Drug" In Combination With Metformin In Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control On Metformin Therapy Alone

2002-2002: Phase IIIb, A Prospective, Randomized, Double-Blind, Parallel-Group, Study Comparing The Antiproteinuric Effects Of "Study Drug" And "Study Drug" When Each Are Added To "Study Drug" 100mg In Treating Diabetic Hypertensive Subjects With Proteinuria

2002-2002: Phase III, A Randomized, Double-Blind, Safety, And Efficacy Pilot Study Of

“Study Drug” Versus “Study Drug” As First-Line Antihypertensive Therapy In Patients With Type II Diabetes Mellitus And Hypertension

2002-2002: Phase III, A Randomized, Double-Blind, Dose Ranging, Dose Comparison-Controlled Trial To Determine The Safety And Efficacy Of An Investigational Study Drug In Subjects With Type II Diabetes

2002-2002: Phase III, A Double-Blind, Placebo-Controlled, Randomized, Multicenter Study To Investigate The Safety And Efficacy Of “Study Drug” Over 12 Weeks Followed By A 4-week Re-randomized Treatment Period In Diarrhea-Predominant Irritable Bowel Syndrome Subjects

2001-2002: Phase III, “An Open-label, Multinational, Multicenter, Extension Trial To Assess The Long-Term Safety And Efficacy Of “Study Drug” In Subjects In The ZD4522 Clinical Trial Program

2001-2002: Phase III, Randomized, Open-Label, Multicenter Trial Of The Safety And Effectiveness Of “Study Drug” and “Study Drug” In Outpatients With Respiratory Tract Infections In Usual Care Settings

2001-2002: Phase IV, An Open-Label, Multicenter, Single Group Study To Assess The Bacteriological Eradication, Clinical Efficacy And Safety Of “Study Drug” Given Once Daily For Five Days In The Treatment Of Acute Bacterial Sinusitis (ABS)

2001-2002: Phase III, A Multicenter, Double-Blind, Randomized, Placebo-And Active-Controlled, Parallel Study To Evaluate The Lipid Altering Efficacy And Safety Of “Study Drug” In Patients With Metabolic Syndrome And Dyslipidemia

2001-2002: Phase IV, A Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter, Flexible Dose Study To Evaluate The Efficacy And Safety Of “Study Drug” In Males With Erectile Dysfunction And Congestive Heart Failure

2001-2002: Phase IV, A Randomized, Open Label 16- Week Study Comparing Breakthrough Bleeding Profiles Of Women On “Study Drug” 1/5 Or “Study Drug”

2001-2002: Phase III, A Double-Blind Placebo-Controlled, Parallel Group Design Study Of Two Doses Of “Study Drug” Vs. Placebo For The Treatment Of Sexual Dysfunction (Hypoactive Desire) In Postmenopausal Women

2001-2002: Phase III, Study Of The Efficacy And Tolerability Of “Study Drug” And Twice Daily “Study Drug” Vs. Placebo In The Treatment Of Hispanic Subjects With Osteoarthritis Of The Knee

2001-2002: Phase III, A multicenter, Eight-Week Treatment, Single Step Titration, Open-Label Study Assessing The Percentage Of Dyslipidemic Patients Achieving LDL Cholesterol Target With “Study Drug” Starting Doses Of 10 mg, 20 mg, 40 mg, And 80mg

2001-2002: Phase III, Long-Term, Open-Label, Safety And Tolerability Study Of “Study Drug” In Subjects With Primary Hypercholesterolemia

2001-2002: Phase III, Omapatrilat Cardiovascular Treatment Assessment Versus Enalapril

2001-2001: Phase III, “A Double-Blind Randomized Study To Evaluate The Effects Of Fixed Combination “Study Drug” Therapy In Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control On Half-Maximum To Maximum Of The Labeled Doses Of “Study Drug”

2000-2002: A Phase IV, Randomized, Placebo-Controlled, Parallel Group (With Subject Option For The Treatment Switch), Double-Blind Study With Open Label Treatment To Evaluate The Efficacy And Safety Of “Study Drug” In Hispanic Americans With Erectile Dysfunction

2000-2002: A Phase III, Multicenter, Randomized, Double-Blind, Parallel Group Trial Comparing The Safety And Efficacy Of “Study Drug” To “Study Drug” As First Line Therapy In Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control With Diet And Exercise

2000-2002: A Phase III, Randomized, Double-Blind, Placebo Controlled Trial To Evaluate The Safety And Efficacy Of "Study Drug" Added On To A Background Of "Study Drug" Tablets In/Subjects With Type 2 Diabetes Mellitus Who have Inadequate Glycemic Control On "Study Drug" Therapy

2000-2001: A Phase III, Double-Blind, Placebo-Controlled, Parallel Group, Dose-Response Study To Evaluate The Efficacy And Safety Of "Study Drug" Versus Placebo In The Treatment Of Pain Associated With Diabetic Peripheral Polyneuropathy

2000-2002: A Phase III, Randomized, Placebo Controlled, Double Blinded Trial Of "Study Drug" To Repair Hypokalemia And Maintain Serum Potassium In Hypertensive Patients Treated With Diuretic

2000-2001: A Phase III, "A Multicenter, Randomized, Double-Blind Study Of The Efficacy And Safety Of "Study Drug" And "Study Drug" In The Treatment Of Subjects With Hypertension"

2000-2000: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel, 9 Week Dose Ranging Study Of "Study Drug" In The Treatment Of Mild To Moderate Hypertension

2000-2000: A Phase III, Twenty-Four Week Randomized, Open Label Study Of Health Care Resource Use, Quality Of Life And Productivity With "Study Drug" 1mg Twice Daily Versus Traditional Therapy In Females With Irritable Bowel Syndrome Whose Predominant Bowel Symptom Is Diarrhea

1999-2002: John A. Hartford Foundation Depression Initiative: IMPACT Study (In Seniors)

1999-2002: A Phase III, Double-Blind Efficacy And Safety Study Of One Dose Of "Study Drug" (10 mg) Compared To Placebo in Subjects With Primary Hypercholesterolemia

1999-2002: A 24-Week Randomized Double-Blind Multicenter Trial To Evaluate The Efficacy And Safety Of Starting And Maximum Doses Of "Study Drug" And "Study Drug" In The Treatment Of Subjects With Hypercholesterolemia And Documented Atherosclerosis

1999-2000: A Twenty-Four Week, Randomized, Double-Blind Study Of The Effects Of "Study Drug" Versus "Study Drug" And Placebo Administered Orally To Patients With Intermittent Claudication Secondary To Peripheral Arterial Disease

1999-2000: A Phase III, Randomized, Double-Blind, Active Control Trial To Evaluate The Safety And Efficacy Of A Fixed Combination "Study Drug" Product In Patients With Type II Diabetes Mellitus Who Have Inadequate Glycemic Control On Maximum Dose Sulfonylurea Monotherapy

1999-1999: A Randomized, Double-Blind, Amlodipine And Losartan-Controlled Study Of "Study Drug" In Subjects With Mild To Moderate Hypertension

1998-2002: Double-Blind, Randomized, Placebo-Controlled Study Of "Study Drug" As Prevention Of Cerebrovascular Events In Patients With A Previous Transient Ischemic Attack (TIA) Or Stroke

1998-1999: Assessment Of "Study Drug" For Adjunctive Treatment With "Study Drug" For Weight Loss In Obese Patients In A Large 16-Week, Multicenter, Open-Label Trial In Physician Practice Settings

1998-1999: A Study Of The Antiproteinuric Effects Of "Study Drug" And "Study Drug" In Type II Diabetes With Hypertension And Microalbuminuria Or Overt Neuropathy

1998-1999: "A Double-Blind, Placebo-Controlled, Randomized Trial To Determine The Effects Of A Range Of Doses Of "Study Drug" Administered Once Or Twice A Day In Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control With Diet and Exercise"

1998-1999: "The Efficacy And Safety Of "Study Drug" Added To Hydrochlorothiazide For The Treatment Of Hypertension In Subjects Non-Responsive To Hydrochlorothiazide Alone"

1998-1999: "A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Elective Titration Study Of "Study Drug" In The Treatment Of Mild To Moderate Hypertension"

1998-1999: "A Multicenter, Randomized, Double-Blind Study Of The Efficacy And Safety Of "Study Drug" And "Study Drug" In The Treatment Of Subjects With Severe Hypertension"

1998: "A Randomized, Double-Blind, Active- And Placebo-Controlled, Parallel Group, Dose Response Study Of The Safety, Pharmacokinetics And Effect On Pain And Function Of "Study Drug" In Subjects With Osteoarthritis Of The Knee"

1998: "CONVINCE Protocol for Mild Hypertension"

Signature and Date